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Introduction {#sec1}
============

Drug discovery is a time-consuming and resource-intensive process that requires large investments by pharmaceutical industry corporations as well as governments ([@bib47]). Developing a new drug from the original idea to the launch of a finished product is usually a complicated process that takes 10--15 years and costs US\$0.5 billion to US\$2.6 billion ([@bib30], [@bib61]). Considerations of all possible organic molecules has led to the concept of "chemical space," which is considered to include at least 10^60^ molecules ([@bib50]). Only a small fraction of chemical space can be developed into final drugs ([@bib37]). Exploring chemical space through synthesis and screening is the conventional method used when searching for new drugs, but it is also a large burden in drug discovery. Consequently, the development of strategies to efficiently explore chemical space for drug discovery is an important scientific issue.

Hit-to-lead (H2L) optimization while working in bioactive and accessible chemical space is crucial to the success of drug discovery and is thus currently a cutting edge research area in medicinal chemistry ([@bib49], [@bib60]). H2L optimization involves evaluation and structural optimization of a hit compound to identify promising lead compounds ([@bib31], [@bib46]). The key to starting H2L optimization is to identify an appropriate scaffold with the desired basic bioactivity that can provide a sufficient number of high-quality analogues. Owing to the development of new technologies in drug design, such as virtual screening, combinatorial chemistry, and high-throughput screening, discovering an appropriate scaffold with the desired basic bioactivity is not difficult. However, 5,000--10,000 compounds still have to be synthesized in the laboratory and screened in the H2L stage to identify a clinical lead ([@bib41]). The large number of analogues that need to be synthesized and validated experimentally in this step make H2L, a complex multiple-property optimization process, rate-limiting in drug discovery ([@bib28]).

To overcome this bottleneck, rational design approaches are widely used in the H2L stage of drug discovery, and many successful applications have been reported ([@bib7], [@bib17], [@bib19], [@bib25], [@bib27], [@bib33], [@bib44], [@bib45], [@bib51], [@bib54]). One major trend is fragment-based drug discovery ([@bib18], [@bib26]). Graeme et al. developed a fragment-based method to optimize the pyrazole carboxylic ester scaffold with low affinity into a potent cyclic nucleotide phosphodiesterase IV (PDE4) inhibitor by synthesizing only 21 compounds ([@bib4]). Another example is the discovery of the selective B cell CLL/lymphoma 2 (BCL-2) drug ABT-199 by screening fragments on two distinct regions of BCL-2 ([@bib52]). Artificial intelligence (AI) is another emerging trend. In a recent work, Zhavoronkov et al. developed a deep generative model for the rapid identification of potent discoidin domain receptor 1 (DDR1) kinase drug leads by synthesizing 40 compounds ([@bib61]). These rational design approaches are used to explore key interactions and to understand the relationships between structure and activity, and they are well suited for the discovery of new ligands with improved binding, selectivity, or other pharmacological properties. However, in the H2L stage, such approaches also encounter difficulties such as targeting unreachable chemical space, poor applicability of data-driven models, and inefficient deduction and decision-making on the next leads to be synthesized, which remain formidable challenges.

We developed an efficient and general approach called auto *in silico* ligand directing evolution (AILDE) for the rapid identification of drug leads in accessible chemical space. AILDE performs minor chemical modifications on the scaffold of a hit compound, and these modifications can result in minimal losses or, in some cases, even increases in ligand efficiency. Hence, this strategy can explore the chemical space around each hit in a series of compounds and drive the evolution of hit compounds into more "clinic-ready" lead structures. The deduction and decision-making on the leads, as well as the applicability of AILDE, have been rigorously validated on 19 drug targets with 157 ligands. The predicted binding affinities were linearly correlated (R^2^ = 0.82) and within 0.31 kcal mol^−1^ on average of the experimental values. We also describe how this approach was applied to discover a potent anticancer drug lead (**5g**) with surprisingly high efficiency.

Owing to their pivotal roles in signal transduction and the regulation of a range of cellular activities, mesenchymal-epithelial transition factor (c-Met) has been established as a promising drug target for the treatment of cancer ([@bib20], [@bib23], [@bib58]). A large number of c-Met kinase inhibitors have been reported over the past few decades ([@bib2], [@bib8], [@bib11], [@bib12], [@bib35], [@bib36]). However, few examples of the discovery of c-Met kinase inhibitor leads have achieved highly efficient optimization using computational design, synthesis, *in vitro* and *in vivo* assays, and cocrystallization validation. We applied AILDE to c-Met and successfully discovered a potent drug lead (**5g**) by synthesizing only eight compounds. Two steps of ligand-directed evolution were performed. Compound **5g** ultimately showed an ∼1,000-fold activity improvement in the enzyme-based assay (IC~50~ = 9.7 nM) compared with **5a**. **5g** also exhibited potent *in vitro* inhibition in a cell-based assay (IC~50~ = 47.3 nM). Moreover, **5g** induced dose-dependent tumor growth inhibition (TGI), with a minimum effective dose (MED/ED~50~, 50% TGI) of ∼8.3 mg/kg. At 25 mg/kg, **5g** showed significant *in vivo* antitumor efficacy (TGI of 82%). The binding mode and interactions seen in the cocrystal structure of compound **5i** (an analogue of **5g**) with c-Met were highly consistent with our predicted result, which confirmed the reliability of our strategy. AILDE may improve the efficiency and effectiveness of the initial stages of drug discovery. We also developed a web service to allow medicinal chemists to easily use AILDE.

Results and Discussion {#sec2}
======================

Small Group Library {#sec2.1}
-------------------

The small group library includes 47 substituents that are from two fragment-based databases, PADFrag (<http://chemyang.ccnu.edu.cn/ccb/database/PADFrag/>) ([@bib59]) and Molinspiration (<https://www.molinspiration.com/>). PADFrag is a searchable web-enabled resource that combines 1,652 FDA-approved drugs, 1,259 commercial pesticides, and 5,919 generated molecular fragments. It was designed for molecule design, and several functions are included in the server, such as viewing, sorting, and fragment extracting. Molinspiration offers a database of substituents and linkers obtained by substructure analysis of a collection of current drugs, development drugs, and other molecules. About 21,000 substituents from 17,000 entries are contained in the database. It has been successfully used in the area of virtual combinatorial chemistry, generation of bioactive molecules, bioisosteric design, and so on. The selection method of the 47 substituents is shown in Transparent Methods. The structures of the substituents are shown in [Figure S1](#mmc1){ref-type="supplementary-material"}.

The Computational Protocol of Ligand-Directed Evolution {#sec2.2}
-------------------------------------------------------

A well-designed and organized computational strategy is a powerful tool for improving computational accuracy and efficiency. AILDE, which combined one-step free energy perturbation (FEP) and molecular dynamics (MD) simulation strategies, was achieved by replacing hydrogen atoms with small groups on the hit compound to generate lead candidates with enhanced potency. MD simulation was first performed on the hit-receptor complex system. We collected 50 snapshots from the equilibrated MD trajectory to obtain a representative ensemble of the binding structures. Then, one-step FEP scanning was introduced. We replaced every hydrogen one-by-one by linking the constructed small groups in each snapshot. Each newly obtained ligand-receptor was refined by using two different minimization methods to obtain the final structures. We only performed molecular mechanics (MM) minimization with the steepest descent and conjugated gradient method in the first method. The second method was realized by adding an MD refinement step after MM minimization. Both methods were used to study the case mentioned previously. We used the MM-PBSA method to evaluate the binding free energies of the refined complex structures. The new lead compounds were finally ranked according to the binding free energy shifts between the lead-receptor and hit-receptor complexes. The details of the workflow of the computational strategy are shown in [Figure 1](#fig1){ref-type="fig"}. When evaluating a large number of changes to a parent ligand, AILDE was orders of magnitude faster than the conventional FEP-based method. The improvement in efficiency was greater when there were more changes on the ligand.Figure 1The Calculation Workflow of AILDEThe computational process includes initialization, MD simulation, one-step FEP scanning, and free energy calculation. In the snapshot minimization, we use two different strategies for comparison.

Dataset Selection {#sec2.3}
-----------------

A collection of protein-ligand structures and bioactivities is prerequisite to evaluate the performance of AILDE. The diverse data to construct a test set were collected according to three criteria: (1) the cocrystal structure of the protein and hit compound is available, (2) the bioactivities of the hit compound and its analogues are available, and (3) the ligands in the dataset show high flexibility. The 19 hit-receptor complexes were collected from published papers ([@bib1], [@bib3], [@bib6], [@bib9], [@bib10], [@bib13], [@bib14], [@bib15], [@bib22], [@bib32], [@bib34], [@bib38], [@bib39], [@bib43], [@bib53], [@bib56], [@bib57]). There were 157 inhibitors with their experimental bioactivity data in the test dataset. These data are shown in the format of IC~50~, *K*~i~, *K*~d~, or EC~50~. These proteins included HIV1-gp120, GSK3, PDK1, and Hsp90 ([Table S1](#mmc1){ref-type="supplementary-material"}). They covered multiple target types, such as viral protein, transferase, kinase, signaling protein, hydrolase, and transcription targets. The hit compounds had different sizes and properties. They were evaluated based on their molecular weight (MW), number of heavy atoms, and number of rotatable bonds ([Table S1](#mmc1){ref-type="supplementary-material"}). The MWs ranged from 184.10 to 460.25 Da. Between 14 and 34 heavy atoms were present. The number of rotatable bonds ranged from 0 to 8. Hence, we considered both rigid and flexible molecules in the dataset. The structures of the hit compounds are shown in [Table S1](#mmc1){ref-type="supplementary-material"}. According to the above analysis, the compounds in our testing set cover a wide range of compound sizes, properties, and target types.

Performance Evaluation and Comparison {#sec2.4}
-------------------------------------

To evaluate the impact of an additional MD simulation on the prediction accuracy, we compared the performance of two minimization methods from the perspective of qualitative and quantitative accuracy. All 19 systems were submitted to AILDE for evaluation. We obtained all the binding free energy shift (ΔΔ*G*~cal~) values between the hit-receptor complexes and the lead-receptor complexes ([Table S2](#mmc2){ref-type="supplementary-material"}). The related experimental binding free energy shift (ΔΔ*G*~exp~) values were calculated by using the collected activity data based on [Equation 4](#mmc1){ref-type="supplementary-material"}. We found that an additional MD refinement may provide a more convergent structure and a more accurate result. We have offered a detailed application example of TNNI3K-benzenesulfonamide system (see [Transparent Methods](#mmc1){ref-type="supplementary-material"} and [Figure S2](#mmc1){ref-type="supplementary-material"}). Finally, we also compared several published H2L strategies with AILDE, and relative to the other methods, AILDE showed a better predictive performance but lower structural diversity.

The qualitative performance of AILDE was first evaluated in terms of specificity, sensitivity, and accuracy. In the dataset, we defined the positive samples (ΔΔ*G*~exp~ ≥ 0, indicates the derivate has lower or equal bioactivity compared with the hit compound) and negative samples (ΔΔ*G*~exp~ \< 0, indicates the derivate has better bioactivity than the hit compound). The numerical values of sensitivity represent the probability of AILDE identifying samples that do in fact have improved bioactivity. The specificity represents the probability of AILDE recognizing samples without giving false-positive results. Accuracy is the proportion of true results, either true positive or true negative, in the total samples. Because we used two minimization methods for one-step FEP scanning, we can summarize the results as follows. (1) For the first minimization method, AILDE identified 75 of the 93 positive samples with a sensitivity (true positive rate) of 80.6% and 56 of 64 negative samples with a specificity (true negative rate) of 87.5%. A total of 131 samples were correctly classified, corresponding to an accuracy of 83.4%, and the predicted binding free energy changes were within 0.71 kcal mol^−1^ of the experimental value on average. (2) For the second minimization method, 85 of the 93 positive samples and 62 of the 64 negative samples were correctly identified, corresponding to a sensitivity of 91.4% and specificity of 96.9%, respectively. The accuracy was 93.6% based on identifying 147 samples correctly of the 157 samples in the dataset, and the predicted binding free energy changes were within 0.31 kcal mol^−1^ of the experimental values on average ([Figure 2](#fig2){ref-type="fig"}A). We observed that both methods achieved a classification accuracy over 80%. Moreover, the accuracy of the second method was over 90%. The second method had a 10% improvement in accuracy and a 0.4 kcal mol^−1^ decrease in deviation compared with the first method, which confirmed that the introduction of an MD refinement step can improve the prediction accuracy. The MD step may further optimize the snapshot toward a more reasonable and convergent state.Figure 2Performance Evaluation of AILDE(A) The details of the predictive results for the total samples under the two minimization strategies; ^a^ true positive, ^b^ false positive, ^c^ false negative, ^d^ true negative, ^e^ TPR = TP/(TP + FN), ^f^ FPR = FP/(FP + TN), ^g^ SPC = TN/(FP + TN), ^h^ FNR = FN/(TP + FN), ^i^ ACC = (TP + TN)/(TP + FP + FN + TN).(B) The ROC curve showing the relationship between the sensitivity and 1-specificity under the two different minimization strategies (blue for strategy 1 and red for strategy 2) for classifying compounds with lower activity (positive samples) or better activity (negative samples) than the hit compound.(C) Scatterplot diagram of the first strategy with correlation coefficient R^2^ = 0.64 (σ = 1.02 kcal mol^−1^) for 157 studied samples.(D) Scatterplot diagram of the second strategy with correlation coefficient R^2^ = 0.82 (σ = 0.54 kcal mol^−1^) for 157 studied samples. The red lines in (C) and (D) correspond to ideal predictions, and the blue dashed lines mark the 1σ region. The values on the x axis and y axis represent the ΔΔ*G*~exp~ value and ΔΔ*G*~cal~ values, respectively.

We then assessed the classification ability of AILDE based on the receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC). An ROC curve plots sensitivity versus (1-specificity) in the range of 0.0--1.0 according to different thresholds. An AUC value of 1.0 represents a perfect classifier and 0.5 represents a classifier that is no better than random. The ROC curves are shown in [Figure 2](#fig2){ref-type="fig"}B and are labeled with the AUC values. The first minimization method showed AUC = 0.875 and the second showed AUC = 0.959. The higher AUC value further confirms the better predictive performance achieved with the introduction of the MD refinement step.

A linear equation can be used to describe the relationship between two sets of variables and show how one variable changes in a linear manner as a function of changes in the other variable. For further study, the linear correlation between ΔΔ*G*~cal~ and ΔΔ*G*~exp~ was obtained with correlation coefficients R^2^ = 0.64 (SD \[σ\] = 1.02 kcal mol^−1^) and 0.82 (σ = 0.54 kcal mol^−1^) ([Figures 2](#fig2){ref-type="fig"}C and 2D) for the first and second strategies, respectively. The linear relationships (R^2^) of both methods are over 0.6, confirming the prediction reliability of our strategy. The second minimization method resulted in a stronger correlation. The dots in the scatterplot diagram of the second strategy (see [Figures 2](#fig2){ref-type="fig"}C and 2D) were more tightly clustered than those in the plot of the first strategy. Therefore, the introduction of an MD refinement step may improve the energy convergence result, which supports our previously mentioned conclusion.

We also compared the accuracies of published computational H2L strategies and AILDE ([@bib5], [@bib7], [@bib16], [@bib24], [@bib29], [@bib40], [@bib42], [@bib48], [@bib55], [@bib62]). The prediction results obtained with the different methods are summarized in [Table S3](#mmc1){ref-type="supplementary-material"}. The accuracies are divided into quantitative and qualitative results. Quantitative accuracy is determined based on the linear correlation coefficient (R or R^2^) between the experimental and calculated results. Qualitative accuracy was indicated by the AUC value or the accuracy of the model to discriminate samples into positive or negative. Compared with the ligand-based H2L methods, AILDE possesses better accuracy both quantitatively and qualitatively. The R^2^ value (0.82) is higher than the highest R^2^ value (0.78) achieved with other ligand-based methods. Most importantly, our strategy is better suited for model expansion because it has a broader target selection scope and a larger number of samples than other ligand-based methods. Most structure-based H2L strategies are based on docking, MD, or MM-PB(GB)SA. The prediction accuracy of docking methods is not over 0.70, although the computational model can be applied on a larger number of systems. The accuracy of the MM-PB(GB)SA method was highest (0.81), but it was limited to the smallest number of samples. In order to compare the diversity of the structures generated by the strategies from a starting point to the potential lead compound, we calculated the Tanimoto coefficient between the initial skeleton and final most activated compound in every study (shown in [Table S3](#mmc1){ref-type="supplementary-material"}) by using RDKit packages ([@bib21]). The compound **5a** (hit) and **5g** (lead), discovered by us as c-Met inhibitors (seen in [Figure 3](#fig3){ref-type="fig"}), were used to calculate the Tanimoto coefficient for AILDE. It shows that AILDE has the highest Tanimoto coefficient (0.709) compared with other methods, which proves the less diversity of the structures generated by AILDE during the optimization process. By comparison, we can see that, although AILDE has higher prediction accuracy and is applicable to a considerably larger number of test samples relative to other structure-based strategies, AILDE has certain limitation compared with other methods in exploring more extensive chemical space.Figure 3The Process of Structural Directed Evolution from Hit Compound **5a** with Enzyme-Based IC~50~ Values

Discovery of c-Met Inhibitors {#sec2.5}
-----------------------------

We applied AILDE to the H2L optimization of c-Met inhibitors to discover a potent anticancer lead. Compound **5a** was identified in a previous virtual screening of an in-house database as a hit compound targeting c-Met with weak *in vitro* activity (IC~50~ = 9,279 nM). Two steps of ligand-directed evolution were performed, and the process is shown in [Figure 3](#fig3){ref-type="fig"}. In the first step, we replaced block A with other groups to improve the activity because no obvious interactions were detected between the thiophene and the surrounding residues and enough space was observed between the thieno\[3,2-d\]pyrimidine and the receptor (PDB: [3F82](pdb:3F82){#intref0020}) in the docking experiment ([Figure S3](#mmc1){ref-type="supplementary-material"}). The thieno\[3,2-d\]pyrimidin-4-yl motif (block A) in compound **5a** was replaced with a total of 9,403 medicinal fragments in PADFrag ([@bib59]). The prediction result provided new compounds with different blocks, and some of the top-ranked structures are shown in [Figure S4](#mmc1){ref-type="supplementary-material"}. Compounds **5b** (ΔΔ*G*~cal~ = −1.31 kcal mol^−1^) and **5c** (ΔΔ*G*~cal~ = −1.45 kcal mol^−1^) were selected for the enzyme-based activity test. **5c**, which possessed a quinazoline moiety, displayed the most promise for further modifications to improve druggability and a moderate c-Met inhibitory activity (IC~50~ = 602.5 nM). **5c** showed 15-fold higher activity than **5a**.

The second step was designed to perform the small-substituent-directed evolution because large modifications may reduce the ligand efficiency. The 10 most commonly used substituents (-CH~3~, -OH, -F, -Cl, -Br, -COOH, -CF~3~, -NH~2~, -NO~2~, and -OCH~3~) in the small group library were scanned in the R^1^ position of compound **5c**. The five top-ranked and easily synthesizable compounds (**5d** ∼ **h**) were synthesized for further bioassay tests. The calculated binding free energy shifts compared with **5a** are shown in [Table 1](#tbl1){ref-type="table"}. The synthetic route is shown in [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}. All the synthesized compounds were structurally characterized by ^1^H NMR and ^13^C NMR spectroscopy and HRMS (shown in [Figures S7--S22](#mmc1){ref-type="supplementary-material"}). Resulting compounds **5d--h** exhibited 8.6- to 62.1-fold increases in enzyme potency compared with **5c** and 133.1- to 956.6-fold increases compared with **5a**. In particular, compound **5g** (R^1^ = 4-F) exhibited significant inhibition potency (IC~50~ = 9.7 and 47.3 nM) in both the enzyme-based and cell-based assays. By using AILDE, a c-Met inhibitor with great potential (**5g**) was finally found in a highly efficient manner, and it showed an ∼1,000-fold improvement in activity compared with the hit compound (**5a**).Table 1Structures and c-Met Inhibitory Potencies of Compounds **5a--5h** with Calculated ΔΔ*G*~cal~ Values Compared with **5a**![](fx2.gif)CompoundBlock AR^1^c-Met (IC~50~, nM)ΔΔ*G*~cal~ (kcal mol^−1^)Enzyme-Based[a](#tblfn1){ref-type="table-fn"}Cell-Based[b](#tblfn2){ref-type="table-fn"}**5a**![](fx3.gif)4-OMe9,279-[c](#tblfn3){ref-type="table-fn"}0**5b**![](fx4.gif)4-OMe1,000-[c](#tblfn3){ref-type="table-fn"}−1.31**5c**![](fx5.gif)4-OMe602.5-[c](#tblfn3){ref-type="table-fn"}−1.45**5d**![](fx5.gif)4-CF~3~40.324,987−3.12**5e**![](fx5.gif)2-F28.8194.2−3.12**5f**![](fx5.gif)3-F67.6600.8−2.95**5g**![](fx5.gif)4-F9.747.3−3.15**5h**![](fx5.gif)-H69.7358.4−3.03[^3][^4][^5]

Compound **5g** was then subjected to pharmacokinetic (PK) evaluation and tumor growth inhibition studies in mice. As shown in [Table 2](#tbl2){ref-type="table"}, after oral administration (10 mg/kg) in rats, **5g** displayed an excellent overall PK profile with a high C~max~ (12.7 μg/mL), AUC~0-∞~ (481.2 μg·h/mL), and *F* (57%). Moreover, as shown in [Figure 4](#fig4){ref-type="fig"}, **5g** induced dose-dependent TGI, with an ED~50~ of 8.3 mg/kg. At 25 mg/kg, **5g** exhibited significant *in vivo* antitumor efficacy (TGI of 82%). More importantly, partial tumor regression (PR 2/6, TGI of 97%) was observed at a higher dose of **5g** (75 mg/kg), and the PKs of **5g** in beagle dogs and cynomolgus monkeys were outstanding with favorable oral bioavailabilities (*F* = 73 and 48.0%, respectively, shown in [Table S4](#mmc1){ref-type="supplementary-material"}) after oral administration. In addition, the 28-day repeat-dose toxicity studies on rats showed that **5g** has a good safety performance (safety index \>40-fold shown in the Transparent Methods) (shown in [Figure S23](#mmc1){ref-type="supplementary-material"}). Taken together, although numerous c-Met inhibitors have been reported, compound **5g** demonstrated a favorable *in vitro* potency, *in vivo* efficacy, PK profile, and safety profile. Therefore, **5g** has been advanced to preclinical studies.Table 2*In Vivo* PK Profiles of Compound **5g** in RatsCompoundRouteDose (mg/kg)*C*~max~ (μg/mL)*T*~max~ (h)*T*~1/2~ (h)AUC~0-∞~ (μg∗ h/mL)CL (L/h/kg)*Vz* (L/kg)*F* (%)**5g**p.o.1012.72.026.7481.20.020.857i.v.530.70.0316.8420.60.010.3[^6][^7]Figure 4*In Vivo* Bioassay of Compound **5g**(A) *In vivo* TGI activity of compound **5g** in rats. ^a^ Administered orally at corresponding dose once daily for 21 consecutive days (70% PEG-400/H~2~O); ^b^ tumor growth inhibition value, ∗:p \< 0.05, ∗∗:p \< 0.01; ^c^ partial regression.(B) Tumor growth inhibition of **5g** in the U87-MG xenograft model in mice.(C) Tumor pictures at the end of the *in vivo* antitumor activity assay.

Cocrystal Structure of c-Met and the Inhibitor {#sec2.6}
----------------------------------------------

To validate the accuracy of the simulated structure, the cocrystal structure of c-Met and the inhibitor was obtained. We have tried to cultivate the cocrystal structure of **5g** and c-Met but failed because of the slightly poor solubility of **5g**. Therefore, we synthesized compound **5i** (IC~50~ = 27.1 nM, enzyme inhibition activity), which is closely related to the structure of **5g** but has better solubility, to obtain the cocrystal structure with c-Met. The only difference between **5i** and **5g** is that **5i** has a morpholinomethyl group linked to the methoxy moiety of **5g**. We finally determined the X-ray crystal structure of compound **5i** bound to c-Met at a resolution of 1.80 Å. As shown in [Figure 5](#fig5){ref-type="fig"}A, the quinazoline group lies in the adenine pocket and forms an H-bond with the backbone N of Met1160 in the hinge. The quinazoline-linked fluorophenoxy group forms a π-π interaction with residue Phe1223 in the DFG (Asp1222-Phe1223-Gly1224) motif. The DFG-out conformation opens a hydrophobic allosteric pocket that is occupied by the terminal 4-fluorophenyl group. In addition to forming an H-bond with residue Lys1110 in the N-lobe, the naphthyridin-4-one group also binds with an allosteric channel and directly interacts with DFG residue Asp1222 through the formation of an H-bond. The morpholine group extends into the solvent. We compared our predicted binding mode of **5g** with the X-ray crystal model of **5i** and found that the binding model of **5g** was very close to that of **5i** ([Figure 5](#fig5){ref-type="fig"}B). The same parts of their skeleton have a root-mean-square deviation (RMSD) of 0.25 Å. **5g** has the same H-bonding and hydrophobic interactions as **5i** in the crystal complex. The high consistency of the binding modes and interactions in the predicted and experimental crystal structures confirmed the reliability of our computational strategy.Figure 5X-ray Structure of **5i** and Modeled Structure of **5g** Bound to c-Met(A) The X-ray structure of **5i** bound to c-Met, **5i** is shown with yellow ball-and-stick model, residues from c-Met are shown as magenta sticks, H-bonds are shown as red, dotted lines.(B) The superimposition of the modeled and X-ray crystal structures of c-Met in complex with ligands (**5g** and **5i**). The modeled structure of **5g** is shown in green lines, and the receptor (PDB: [3F82](pdb:3F82){#intref0050}) is shown in blue sticks and cartoon. The X-ray structure of **5i** is given by the yellow lines, with the receptor as magenta sticks and cartoon.

AILDE Server Implementation {#sec2.7}
---------------------------

A freely accessible web server also named AILDE was constructed to allow medicinal chemists to easily use AILDE. The AILDE web server includes the front end and background applications. The architecture of the AILDE web server is shown in [Figure S24](#mmc1){ref-type="supplementary-material"}. The front end consists of a client layer and a resulting browse layer. The client layer provides a user-friendly entry for the user to submit computational tasks. Users may also obtain comprehensive instruction about how to use AILDE from the client layer. The resulting browsing layer offers output formats for users to better understand the results. The background was coded in Python to finish the computational process. The server is managed by Maui-3.3.1 and Torque-6.0.1 on a supercomputing cluster in our laboratory (including 48 computing nodes with 40 CPUs each, 20 computing nodes with 4 GPUs each, 8 computing nodes with 40 CPUs and 256 GB large memory each, 3 storage servers, and 1 management server). The calculation time for a job depends largely on the size of the complex and the hardware status. Take the example job of the server as an example, the protein has 380 residues in total, the MD simulation step (about 6 ns) takes about 1.5 h (4 GPU parallel), the hydrogen replacement and minimization step (for first minimization strategy) takes 3 min per newly obtained lead compound (25 CPUs parallel for 50 snapshots of every compound). The free energy calculation step takes 4 min per compound (4 CPUs parallel). The compound in the example has 17 hydrogens and there are 10 substituents on the server. It will generate 170 new compounds in total. The total time cost of the example job is 1.5 h + 3 min ∗ 170 + 4 min ∗ 170 = 21.3 h and it takes less than 1 day to finish the job. The wizard of the AILDE server is shown in [Figure 6](#fig6){ref-type="fig"}, and a detailed description of how to use the server can be found in the Transparent Methods. To enable users to use AILDE in a more private way, we have also provided an offline version of our code on GitHub (<https://github.com/fwangccnu/AILDE>) for scientists to download and use.Figure 6The Detailed Wizard of AILDE Server to Offer a Intuitive View for Users to Explore ItAILDE server wizard: (1) uploading of a hit-protein complex; (2) selection of a hit compound; (3) hydrogen serial numbers; (4) table with details about the new leads, ΔΔ*G* and activity fold-changes; (5) heatmap showing the relationship matrix between the substituent positions and substituents (darker red colors indicate compounds with higher activities); (6) histogram illustrating the overall result based on substituent positions, which helps to elucidate which positions possess the most potential for transformation; (7) 3D viewer showing the binding mode of every compound with the target protein.

Limitations of the Study {#sec2.8}
------------------------

AILDE reasonably relies on the resemblance assumption between the binding mode of hit-receptor and lead-receptor and adequacy of the conformational sampling, so it is the reliable prediction results when binding mode of the lead compound relative to the hit compound does not change much. We can also see that AILDE has certain limitation compared with other methods in exploring more extensive chemical space, although it has higher prediction accuracy and is applicable to a considerably larger number of test samples.

Resource Availability {#sec2.9}
---------------------

### Lead Contact {#sec2.9.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Gefei Hao (<gefei_hao@foxmail.com>).

### Materials Availability {#sec2.9.2}

All unique/stable reagents generated in this study will be made available on request, but we may require a payment and/or a completed Materials Transfer Agreement if there is potential for commercial application.

### Data and Code Availability {#sec2.9.3}

The online web service of AILDE can be accessed from <http://chemyang.ccnu.edu.cn/ccb/server/AILDE>. The offline version of AILDE program can be downloaded from <https://github.com/fwangccnu/AILDE>.

Methods {#sec3}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================
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